HROW News and Press, Harrow Health Inc.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24 th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, C...

2024-05-14 13:44:42 ET More on mid-day movers & stocks. JanOne to acquire blockchain financial technology provider ALT 5 Sigma Financial information for JanOne Financial information for Mmtec Seeking Alpha’s Quant Rating on ProKidney Histor...

Harrow Health, Inc. (NASDAQ: HROW) is one of today's top gainers. The company's shares have moved 33.64% on the day to $16.11. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding busi...

2024-05-14 10:48:13 ET Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript May 14, 2024, 08:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference Call Participants Jeffrey Cohen -...

2024-05-14 10:00:29 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Health...

2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...

2024-05-13 16:19:50 ET More on Harrow Health Harrow: Merits A Buy On Sales Potential Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript Harrow Health Q4 2023 Earnings Preview Seekin...

First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable fo...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing p...